Us-china Biomedical Technology (CLDS) Annual Balance Sheets

Annual · GAAP · USD millions
Access CLDS quarterly Balance Sheets →
The table below presents a historical view of Us-china Biomedical Technology's balance sheet, supporting analysis of financial position trends.
Annual Report, GAAP in USD millions
ITEM
(Feb 28 2019)
(Feb 28 2018) (Feb 28 2017) (Feb 28 2015) (Feb 28 2014)
Assets
Cash & cash equivalent0.04
Deposits Assets, Current AS0.00
Cash & Short-term Investments0.00
Accounts receivable0.00
Other Current Assets0.00
Prepaid Expense, Current AS0.02
Total Current Assets0.06
Deposits Assets, Noncurrent AS0.02
Other Assets, Noncurrent0.00
Total Assets0.08
Liabilities
Accounts Payable, Current AC0.02
Employee-related Liabilities, Current AC0.01
Notes and Loans Payable, Current LO0.00
Other Liabilities, Current0.00
Deferred Rent Credit, Current DE0.01
Total Current Liabilities0.04
Total Long-term Debt0.00
Other liabilities, Noncurrent0.04
Total Liabilities0.08
Stockholders' Equity
Development Stage Enterprise Deficit Accumulated During Development Stage-
Common Stock Value0.02
Additional Paid In Capital Common Stock2.92
Retained Earnings / Accumulated Deficit-2.94
Other Equity0.00
Common Stockholder's Equity0.00
Total Stockholder's Equity0.00
Liabilities & Stockholder's Equity0.08
4 historic quarters locked

Sign in to unlock the full Us-china Biomedical Technology balance sheet history.

About CLDS Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.